BRIEF—Aurobindo subsidiary enters into China JV

Dutch drugmaker Helix Healthcare, a subsidiary of India’s Aurobindo Pharma, has entered into a joint venture with Shandong Luoxin Pharmaceutical for the manufacture of a nebuliser inhaler and other products.

The products will be marketed in China, the USA and in Europe.

Helix will take a 30% stake, and Luoxin will own 70% of the new entity. Luoxin will appoint three directors and Helix will appoint one director to the board.